deltatrials
Completed NA INTERVENTIONAL 1-arm NCT01879657

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

An Open-label, Single-dose, Clinical Trial of 68Ga-DOTATATE (GalioMedix™) PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Sponsor: Excel Diagnostics and Nuclear Oncology Center

Conditions Neuroendocrine Carcinoma
Interventions 111In-pentetreotide OctreoScan 68Ga-DOTATATE MRI PET/CT
Updated 13 times since 2017 Last updated: Aug 4, 2025 Started: Mar 1, 2013 Primary completion: Dec 30, 2015 Completion: Dec 5, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Neuroendocrine Carcinoma, this trial is completed. The trial is conducted by Excel Diagnostics and Nuclear Oncology Center and has accumulated 13 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2023 · 27 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed NA

  2. Aug 2025 — Sep 2025 [monthly]

    Completed NA

  3. Sep 2024 — Aug 2025 [monthly]

    Completed NA

  4. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  5. May 2023 — Jul 2024 [monthly]

    Completed NA

    Phase: PHASE1_PHASE2 → NA

▶ Show 8 earlier versions

  1. Apr 2023 — May 2023 [monthly]

    Completed PHASE1_PHASE2

  2. Jan 2021 — Apr 2023 [monthly]

    Completed PHASE1_PHASE2

  3. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Unknown Status → Completed

  4. Jun 2018 — Nov 2020 [monthly]

    Unknown Status PHASE1_PHASE2

  5. Feb 2018 — Jun 2018 [monthly]

    Unknown Status PHASE1_PHASE2

  6. Sep 2017 — Feb 2018 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  7. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Excel Diagnostics and Nuclear Oncology Center
  • Radio Isotope Therapy of America
  • Radiomedix, Inc.
Data source: Radio Isotope Therapy of America

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations